Want to see SE:QLIFE full AI Analyst Report?
Top Page
Qlife Holding AB
(QLIFE)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr1.50
▼(-50.17% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by very weak financial performance—severe unprofitability and ongoing cash burn—despite rapid revenue growth off a small base and improved (now positive) equity. Technicals add a modest additional drag with the stock trading below major moving averages and negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Rapid Revenue Growth
Revenue is expanding rapidly, indicating increasing adoption of Qlife’s diagnostic platform and tests. Although growth starts from a small base, sustained commercial traction could support operating leverage if deployments and recurring consumable use continue to scale.
Negative Factors
Severe Unprofitability
Extremely negative margins show that current revenue is far below the level needed to cover product and operating costs. Persistent losses could limit investment capacity, weaken negotiating power and require further capital before the business reaches scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
Revenue is expanding rapidly, indicating increasing adoption of Qlife’s diagnostic platform and tests. Although growth starts from a small base, sustained commercial traction could support operating leverage if deployments and recurring consumable use continue to scale.
Read all positive factors
Qlife Holding AB (QLIFE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr49.95M
Dividend YieldN/A
Average Volume (3M)47.77K
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue Growth226.89%
EPS Growth57.26%
CountrySE
Employees2
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.89
Shares Outstanding28,874,178
10 Day Avg. Volume39,836
30 Day Avg. Volume47,768
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.74
Price to Sales (P/S)109.73
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-126.16
Revenue Forecast (FY)kr116.00M
Qlife Holding AB Business Overview & Revenue Model
Company Description
Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a compre...
How the Company Makes Money
Qlife Holding AB makes money primarily by commercializing its diagnostic platform and the associated consumables used to run tests. The core revenue model typically combines (1) sales or leasing of instrumentation (the analyzer/platform), and (2) ...
Qlife Holding AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 863.00K | 324.00K | 50.00K | 244.00K | 17.99M | 39.61M |
| Gross Profit | -13.73M | -18.11M | -158.00K | -6.31M | -10.75M | 44.54M |
| EBITDA | -18.23M | -18.11M | -12.46M | -150.50M | -78.05M | -35.13M |
| Net Income | -20.30M | -20.56M | -55.98M | -159.96M | -93.14M | -38.80M |
Balance Sheet | ||||||
| Total Assets | 12.56M | 9.63M | 11.64M | 39.05M | 192.65M | 193.44M |
| Cash, Cash Equivalents and Short-Term Investments | 4.36M | 1.42M | 2.71M | 1.66M | 14.55M | 73.46M |
| Total Debt | 8.35M | 14.44M | 8.70M | 20.25M | 52.44M | 4.72M |
| Total Liabilities | 9.91M | 17.14M | 13.07M | 62.17M | 101.50M | 30.26M |
| Stockholders Equity | 2.65M | -7.51M | -1.43M | -23.12M | 91.15M | 132.50M |
Cash Flow | ||||||
| Free Cash Flow | -10.92M | -21.49M | -54.17M | -62.64M | -90.67M | -52.82M |
| Operating Cash Flow | -18.24M | -21.49M | -37.37M | -41.80M | -47.73M | -26.05M |
| Investing Cash Flow | 0.00 | 0.00 | -16.80M | -20.84M | -42.94M | -26.77M |
| Financing Cash Flow | 21.49M | 20.19M | 55.23M | 49.00M | 32.73M | 106.02M |
Qlife Holding AB Technical Analysis
Negative
3.01
Price Trends
1.85
Negative
1.92
Negative
1.98
Negative
Market Momentum
-0.02
Positive
39.70
Neutral
59.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLIFE, the sentiment is Negative. The current price of 3.01 is above the 20-day moving average (MA) of 1.80, above the 50-day MA of 1.85, and above the 200-day MA of 1.98, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.70 is Neutral, neither overbought nor oversold. The STOCH value of 59.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLIFE.
Qlife Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr3.85B | 29.83 | 14.59% | 1.70% | -1.64% | -14.61% | |
74 Outperform | kr55.80B | 87.46 | 30.26% | 0.38% | 13.94% | 5.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | kr537.68M | -4.82 | -37.43% | ― | 27.40% | 26.07% | |
43 Neutral | kr242.08M | -6.34 | -100.09% | ― | 65.82% | 41.28% | |
42 Neutral | kr49.95M | -0.92 | 987.64% | ― | 226.89% | 57.26% | |
41 Neutral | kr235.50M | -1.05 | -303.61% | ― | 51.21% | 42.24% |
* Healthcare Sector Average
SE:QLIFE
Qlife Holding AB
1.73
-1.46
-45.70%
SE:CEVI
CellaVision AB
161.40
-10.77
-6.26%
SE:SEZI
Senzime AB
3.42
-2.78
-44.84%
SE:SCIB
SciBase Holding AB
16.75
-11.14
-39.94%
SE:SECT.B
Sectra AB Class B
286.00
-25.71
-8.25%
SE:ACARIX
Acarix AB
0.22
-0.09
-30.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.